Karma-FSH® contains a purified hormone obtained from Human Menopausal urine having 75 I.U. / 150 I.U. FSH. In patients showing normal or high LH, require preparations without LH activity, this character belongs to FSH.
FSH stimulates both the growth and maturation of follicles, it induces secretion of estrogens and proliferation of the endometrium.
Karma-FSH® is manufactured in BSV Co. (Bioscience Gmbh) and is developed by Homa Pharmed Co. under the license of Karma pharmatech, Germany.
karma-FSH® and Human Chorionic Gonadotrophin (HCG) given in a sequential manner are indicated for induction of ovulation in patients with Polycystic Ovarian Disease (PCOD) who have an elevated LH / FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.
karma-FSH® and HCG may also be used to stimulate the development of multiple oocytes in ovulatory patients participating in an in vivo fertility program.
WARNING:If the ovaries are abnormally enlarged on the last day of karma-FSH® therapy, HCG should not be administered in this course of therapy. This reduces the development of OHSS (Ovarian Hyperstimulation Syndrome).
Karma-FSH® should be administered by intramuscular or subcutaneous injection. The powder for injection should be reconstituted with the Sodium Chloride Injection immediately prior to use. Discard any unused portion.
Karma-FSH® should be stored between °2C–°8C. Do not freeze. Protect from light.
Reconstituted solution should be used immediately after preparation, any unused portion should be discarded.
Keep away from children.
Headache, depression, emotional instability, fever, and pain, large ovary, OHSS, breast tenderness, hot flashes, ovarian disorder (pain and cysts), Cramps, big abdomen, abdominal pain, constipation, diarrhea, dehydration, nausea and vomiting, weight gain, High blood pressure, cervical disease, urinary tract infection, pelvic pain, uterine spasms, vaginal discharge, vaginal spotting